Gilead Sciences vs Bristol-Myers Squibb: why the prices moved differently

• ▲

  Raised 2026 sales outlook and dividend hike Gilead raised its 2026 product sales outlook to $30.1–$30.4 billion and lifted its quarterly dividend 3.8%. Stronger guidance tells investors the HIV business is performing better than expected, which supports the stock price.

  This is the period's biggest new event and directly answers what is driving GILD now.

• ▲

  HIV franchise sales accelerate Quarterly HIV sales rose 12% to $5.7 billion, led by Biktarvy at $3.8 billion and Descovy up 48%. Yeztugo, the twice-yearly prevention shot, jumped to $232 million from $15 million a year earlier, showing the new product is taking off.

  HIV is Gilead's core profit engine, and its growth is the fundamental force behind the raised guidance.

• ◆

  Big acquisition charges create reported losses Gilead recorded $11.2 billion in acquired research charges from buying Arcellx, Tubulis and Ouro Medicines, causing large accounting losses and cutting cash to $3.2 billion from $10.6 billion. This is a real cost of building future growth, but it does not reflect day-to-day operations.

  It is the main counterweight to the good news and explains why reported earnings look weak despite strong sales.

• ▲

  New lenacapavir licensing and FDA approval widen reach Gilead expanded royalty-free lenacapavir licensing to a once-yearly HIV prevention shot across 120 lower-income countries, and won FDA approval for Bixlenvo, a small once-daily HIV pill. Both broaden the HIV portfolio and add future sales.

  These regulatory and access moves extend Gilead's HIV leadership, a key long-term driver.

Based on 8 stories →

• ▲

  Fourth Circuit blocks illegal imports of Biktarvy A federal appeals court upheld an injunction stopping foreign versions of Gilead's top HIV drug Biktarvy from being sold in the U.S. This protects Gilead's U.S. sales and pricing power, supporting the stock.

  This legal win directly protects Gilead's largest revenue stream and removes a competitive threat.

• ▲

  PAHO deal expands lenacapavir access in Latin America Gilead and the Pan American Health Organization agreed to make HIV prevention drug lenacapavir available in 14 Latin American countries. This widens the market for Gilead's prevention portfolio, though pricing terms are still unclear.

  This expands Gilead's global reach for a key growth drug, but the financial impact depends on final pricing.

• ▲

  Morgan Stanley reaffirms Overweight on HIV prevention growth Morgan Stanley kept its buy rating on Gilead, highlighting the HIV prevention franchise. Yeztugo, a twice-yearly shot, is expected to hit $1 billion in first-year sales, with the prevention portfolio at about $4 billion annually and PrEP users more than doubling since 2022.

  Analyst backing and concrete sales targets reinforce confidence in Gilead's growth trajectory.

• ▲

  Gilead's pipeline advances with gamgertamig and anito-cel Lakefront Biotherapeutics plans registrational trials in 2027 for gamgertamig, which Gilead will commercialize. Also, Gilead's anito-cel for multiple myeloma has an FDA decision due in December. These add future growth options beyond HIV.

  Pipeline progress diversifies Gilead's revenue and offers new catalysts, though they are not yet near-term revenue.

Based on 6 stories →

• ▲

  HIV sales growth guidance raised to 9–10% Gilead lifted its full-year HIV sales growth outlook to 9–10% from 8%, citing a $4 billion annualized PrEP business and strong Biktarvy. Higher expected sales mean more profit, which supports a higher stock price.

  This is a direct, new upgrade to the company's core revenue outlook, a key driver of the stock.

• ▲

  FDA approves Bixlenvo, a new single-tablet HIV regimen The FDA approved Bixlenvo, a once-daily single tablet for complex HIV cases. It is the smallest such option and the first for patients who cannot take existing single-tablet therapies, opening a new market and reinforcing Gilead's HIV leadership.

  A new product approval expands the addressable market and future revenue, directly lifting growth prospects.

• ▲

  European Commission expands Trodelvy approval in first-line TNBC The EC approved Trodelvy plus Keytruda for first-line metastatic triple-negative breast cancer, making it the only antibody-drug conjugate plus immunotherapy combo in that setting across the EU. This widens oncology sales and diversifies revenue beyond HIV.

  A major regulatory win in a new indication that boosts the oncology franchise and long-term growth.

• ▲

  Pipeline expands with MacroGenics option and once-weekly HIV data Gilead exercised an option on a MacroGenics bispecific cancer program, and positive Phase 3 results for a once-weekly oral HIV regimen with Merck were announced. These add future growth options, though they are early and not yet near-term revenue.

  New pipeline additions signal longer-term growth potential, which can support a higher valuation.

Based on 6 stories →

• ▲

  Q2 revenue beat and raised full-year guidance Gilead reported Q2 revenue of $7.8 billion, up 10% and above estimates, and raised 2026 product sales guidance to $29.8–$30.1 billion. HIV sales rose 12% to $5.7 billion, with Biktarvy up 7%. This shows the core business is growing faster than expected, which supports a higher stock price.

  This is the period's central event and directly explains the positive fundamental momentum behind GILD.

• ▲

  PrEP franchise tops $1 billion; Yeztugo persistence strong Quarterly PrEP sales doubled year-over-year to over $1 billion for the first time, led by the twice-yearly shot Yeztugo ($232 million, up 40% from Q1). Over 70% of patients stayed on Yeztugo after a year, the best among PrEP options. This growing prevention business adds a new revenue stream and reduces reliance on HIV treatment alone.

  It highlights a key new growth driver that is boosting investor confidence and future sales.

• ▼

  Large acquisition charges push reported EPS deeply negative Gilead's Q2 GAAP EPS was a loss of $8.45, and non-GAAP EPS was a loss of $6.75, due to $11.2 billion in acquired IPR&D expenses from buying Arcellx, Tubulis, and Ouro Medicines. Excluding these one-time charges, EPS would be $8.50–$8.85. The headline loss may scare some investors, but it is an accounting effect, not a cash drain on operations.

  It is the main counterweight in the period and explains why reported earnings look bad despite strong operations.

• ▲

  Analyst reiterates Buy; pipeline advances in oncology and HIV BofA reiterated a Buy rating and $162 price target, citing Yeztugo's persistence and raised guidance. Separately, European regulators backed Trodelvy plus Keytruda for first-line triple-negative breast cancer, and a once-weekly oral HIV regimen with Merck met its Phase 3 goals. These expand future sales opportunities.

  It shows external validation and pipeline progress that support the stock's longer-term growth story.

Based on 8 stories →

• ▲

  Four drug launches planned to diversify beyond HIV Gilead is preparing four drug launches this year, including bulevirtide for hepatitis delta and anito-cel for multiple myeloma. This diversification reduces reliance on HIV and opens new revenue streams, supporting the stock.

  This is a new strategic update that shows Gilead's growth beyond its core HIV business.

• ▲

  Positive Phase 3 results for once-weekly oral HIV regimen Gilead and Merck reported that a once-weekly oral HIV treatment maintained viral suppression in Phase 3 trials, with higher patient satisfaction. This could become the first once-weekly oral option, strengthening Gilead's HIV portfolio.

  This is a new clinical milestone that could lead to a new product and boost future sales.

• ▲

  CHMP recommends Trodelvy plus Keytruda for first-line TNBC The European regulator recommended Trodelvy combined with Keytruda for first-line metastatic triple-negative breast cancer. This expands Trodelvy's use and reinforces its role, potentially increasing sales in Europe.

  This is a new regulatory step that could lead to approval and broader use of a key drug.

• ▲

  Remdesivir evaluated in Ebola trial The WHO began an experimental Ebola trial in Congo, testing Gilead's remdesivir. If effective, it could expand remdesivir's use and demand, though the impact is uncertain and likely small.

  This is a new potential use for an existing drug, but the financial impact is not yet clear.

Based on 6 stories →

• ▲

  FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

  This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

• ▲

  FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

  This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

• ▲

  Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

  New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

• ▼

  Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

  This is a new negative financial disclosure that could cap upside from the positive pipeline news.

Based on 7 stories →

• ▲

  Reblozyl Sales Near $1.3 Billion, FDA Sets 2027 Decision Reblozyl sales hit nearly $1.3 billion in the first half of 2026, up 23%, as it helps replace older drugs losing patent protection. The FDA accepted a supplemental application for use in myelofibrosis-associated anemia, with a decision expected by March 2027. This supports future revenue growth and lifts BMY's outlook.

  Shows a key growth drug's strong sales and a regulatory step that could expand its use, directly supporting BMY's revenue replacement story.

• ▲

  Zenbexus Launch Advances with Onco360 Pharmacy Network Bristol selected Onco360 for the specialty pharmacy network of its newly approved myeloma drug Zenbexus, moving the launch forward. Getting the drug to patients is key to replacing revenue from older myeloma drugs facing generic competition. Successful rollout could add a new blockbuster stream over time.

  Highlights concrete progress in commercializing a new drug that is central to offsetting patent losses.

• ▲

  Bristol Raises Guidance and Builds $2.3 Billion Houston Campus Bristol raised its full-year revenue guidance to about $49–50 billion and announced a $2.3 billion manufacturing campus in Houston. The guidance raise signals confidence in the business, while the plant expands capacity for future drugs. Both support the stock by improving the profit outlook and long-term supply.

  Guidance raise and major investment show management's confidence and capacity for growth, key drivers for the stock.

• ▼

  Patent Cliff and Weak Financials Weigh on Sentiment Analysts warn that Bristol's low valuation reflects looming patent expirations on Revlimid, Pomalyst, and Eliquis, which will cause revenue declines. One report also flagged weak long-term financials: slow revenue growth, falling margins, and declining earnings per share. These concerns keep a lid on the stock despite new drug progress.

  Presents the main counterweight: patent losses and weak financial trends that could pressure the stock even as new drugs grow.

Based on 12 stories →

• ▲

  Growth Portfolio Now 56% of Revenue, EPS Estimates Raised Bristol's growth products (Opdivo, Camzyos, Sotyktu, etc.) now make up 56% of total revenue, up from 51.8% a year ago, with first-half sales up 13%. Analysts have raised 2026 EPS estimates to $6.91 from $6.34, reflecting confidence that new drugs are replacing older ones losing patent protection. This supports a higher stock price.

  Shows the core shift from legacy to growth products that is driving earnings upgrades and investor optimism.

• ▲

  Zenbexus (iberdomide) Wins FDA Approval and Shows Strong Phase 3 Data The FDA granted accelerated approval to Zenbexus for multiple myeloma, the first in a new drug class. In a Phase 3 trial, it doubled the rate of deep responses (MRD-negative complete responses) versus standard treatment. This adds a potential blockbuster revenue stream and validates Bristol's pipeline, lifting the stock.

  A new approved drug with superior efficacy data is a major growth catalyst that directly boosts future revenue expectations.

• ▲

  Sotyktu Shows Sustained Two-Year Efficacy in Psoriatic Arthritis Bristol's Sotyktu maintained strong efficacy and safety over two years in patients with psoriatic arthritis, with responses improving through week 104. This supports the drug's long-term use and potential to capture more market share in a large patient population, adding to revenue growth.

  Long-term data reinforces the commercial potential of a key growth product, supporting revenue forecasts.

• ▲

  Camzyos Approval Expanded to Pediatric Patients The FDA expanded Camzyos's label to include pediatric patients with obstructive hypertrophic cardiomyopathy, making it the only approved therapy for this age group. This broadens the patient pool and strengthens Camzyos's growth trajectory, a positive for Bristol's revenue outlook.

  Label expansion opens a new patient population, directly increasing the drug's market size and sales potential.

Based on 8 stories →

• ▲

  Zenbexus FDA Approval Adds New Myeloma Growth Driver The FDA approved Bristol's oral Zenbexus for relapsed multiple myeloma, a new revenue stream to help replace older drugs losing patent protection. It's an accelerated approval needing confirmatory trials and faces intense competition, so it builds gradually rather than instantly lifting the stock.

  This is a new drug approval that directly adds a future revenue driver for BMY.

• ▼

  J&J's Oral Psoriasis Pill Approved in China, Threatening Sotyktu Johnson & Johnson won Chinese approval for its once-daily oral psoriasis pill, which will compete with Bristol's Sotyktu in a market of over 8 million patients. This adds competitive pressure that could limit Sotyktu's growth in China, weighing on BMY's sentiment.

  New competitive threat in a key market that could slow BMY's psoriasis drug sales.

• ▲

  Five-Year Camzyos Data Reinforces Long-Term Heart Drug Profile Bristol presented five-year data showing its heart drug Camzyos keeps working safely, with most patients improving. This strengthens confidence in a key growth product and supports its use long-term, a positive for BMY's revenue outlook.

  New clinical data that supports the durability and safety of a key growth drug.

• ▼

  CAR-T Safety Concerns After Novartis Deaths; Bristol Pauses Similar Trials Novartis halted CAR-T trials after three patient deaths, and Bristol paused its own similar trials as a precaution. This raises regulatory and safety worries for Bristol's CAR-T programs, adding uncertainty that can pressure the stock until the reviews clear.

  New safety event that directly affects BMY's CAR-T development and investor risk perception.

• ▲

  Arlo-cel Meets Primary Endpoint in Phase 2 Myeloma Trial Bristol's experimental CAR-T therapy arlo-cel met its main goal in a mid-stage myeloma trial, showing strong response rates in hard-to-treat patients. This is a potential first-in-class treatment that could become a future growth driver, boosting optimism about the pipeline.

  New positive clinical trial result that advances a potential new therapy for BMY.

Based on 6 stories →

• ▲

  Bristol Raises 2026 Revenue Guidance on Eliquis Strength Bristol raised full-year 2026 revenue guidance to $49–$50 billion from $46–$47.5 billion, after Eliquis sales grew 19% to $8.6 billion in the first half. The company now expects Eliquis growth of 20–25% for the year, up from 10–15%, and a smaller decline in older drugs. This directly boosts earnings expectations and investor confidence, pushing BMY shares up.

  This is the most significant new positive catalyst, directly raising revenue and profit outlook.

• ▲

  Bristol Partners with Chai Discovery on AI Antibody Discovery Bristol announced a collaboration with Chai Discovery to use AI and machine learning for discovering new therapeutic antibodies. This aims to speed up drug discovery and strengthen the pipeline, supporting long-term growth. While the impact is not immediate, it reinforces Bristol's commitment to innovation and could lead to new revenue streams, positively influencing investor sentiment.

  This new partnership shows Bristol's ongoing investment in AI to enhance pipeline, a key long-term growth driver.

• ▲

  Bristol to Invest $2.3 Billion in Houston Manufacturing Plant Bristol announced a $2.3 billion investment in a new Houston manufacturing campus, part of a larger $40 billion U.S. investment pledge. The plant will produce small-molecule medicines, biologics, and antibody-drug conjugates, creating jobs and expanding capacity. This move supports long-term supply chain resilience and may ease tariff pressures, positively affecting BMY's outlook.

  This new capital investment demonstrates commitment to U.S. manufacturing and could mitigate tariff risks, a positive for the stock.

• ▼

  Revived $6.7 Billion Celgene Lawsuit Adds Legal Uncertainty A federal appeals court reinstated a $6.7 billion lawsuit alleging Bristol delayed FDA approval of certain drugs to avoid paying contingent value rights to former Celgene shareholders. This brings renewed legal and financial uncertainty, potentially leading to a large cash payout and weighing on investor sentiment. The risk premium on BMY may increase, pressuring the stock price.

  This new legal development introduces a significant potential liability, a negative factor for the stock.

Based on 9 stories →

• ▲

  Q2 earnings beat and raised guidance Bristol reported Q2 revenue of $12.97 billion, beating estimates, and raised full-year guidance. Strong sales of Eliquis and newer drugs like Camzyos and Reblozyl drove the beat. This shows the growth portfolio is replacing lost older-drug sales faster than feared, boosting investor confidence and supporting the stock price.

  This is a major positive event that directly impacts BMY's financial outlook and investor confidence.

• ▼

  AstraZeneca merger talks called off After reports of merger talks, AstraZeneca's board decided to call them off, and Reuters reported no discussions ever took place. The potential takeover premium evaporated, removing a catalyst that had briefly lifted BMY shares. This leaves BMY to face its patent cliff alone, weighing on sentiment.

  The merger speculation was a key driver of BMY's stock movement, and its termination is a significant negative development.

• ▲

  FDA approves ZENBEXUS for multiple myeloma The FDA granted accelerated approval to ZENBEXUS, a first-in-class CELMoD therapy, for relapsed multiple myeloma. This new treatment offers a potential revenue stream to help offset losses from older drugs facing patent expirations, strengthening BMY's oncology portfolio and long-term growth prospects.

  This is a new product approval that directly addresses BMY's need to replace lost revenue from expiring patents.

• ▲

  Expanded AI partnerships for drug discovery Bristol expanded its partnership with Nvidia to build a next-generation AI supercomputer and struck a deal with Schrödinger to deploy its AI co-scientist Bunsen. These investments aim to speed up drug discovery and reduce costs, supporting long-term pipeline efficiency and innovation.

  These partnerships highlight BMY's commitment to technological innovation, which could improve future drug development and cost efficiency.

Based on 11 stories →

• ▲

  Q2 beat and raised full-year guidance Bristol reported roughly $13.0 billion in quarterly revenue, beating expectations by $1.23 billion, with cancer drugs driving growth. Adjusted earnings per share jumped about 40% to $2.04. Management raised full-year revenue and profit guidance above consensus, signaling the growth portfolio is replacing lost older-drug sales faster than feared.

  This is the core fundamental news of the period and directly supports a higher valuation for BMY.

• ▲

  Reported AstraZeneca merger talks boost BMY shares The Financial Times and other outlets reported preliminary merger discussions between AstraZeneca and Bristol-Myers Squibb that could create a nearly $400 billion drugmaker. BMY shares rose about 8% in premarket trading before fading to near flat, as investors saw a possible takeover premium but also big antitrust hurdles and doubts a deal gets done.

  This is the single biggest new event moving BMY's stock this period and explains the sharp price reaction.

• ◆

  Deal skepticism and antitrust concerns cap the rally AstraZeneca shares fell about 9% while BMY's early 8% gain faded to near flat, showing the market doubts the deal's value and feasibility. Analysts flagged direct competition in lung cancer between Opdivo and Imfinzi, and estimated neither company has the standalone financial firepower to buy the other outright. A deal may never happen.

  It is the essential counterweight to the merger headline and explains why BMY's initial surge did not hold.

Based on 8 stories →

• ▼

  Cytokinetics launches Myqorzo, competing with Camzyos Cytokinetics launched Myqorzo in the U.S. and Germany for the same heart condition Camzyos treats. With over 275 prescribers already, this new rival could steal Camzyos sales, weighing on BMY's revenue growth.

  This is a new competitive threat that directly pressures a key BMY drug.

• ▼

  Trump administration drug-pricing deals include Bristol Myers Squibb Bristol agreed to voluntary most-favored-nation pricing, aligning some U.S. drug prices with lower prices abroad. With top sellers like Revlimid and Eliquis already facing patent expirations, this makes replacing lost revenue even harder.

  This is a new pricing agreement that directly affects BMY's revenue outlook.

• ▲

  FDA accepts mezigdomide application for multiple myeloma The FDA accepted Bristol's application for mezigdomide in relapsed multiple myeloma, with a decision expected by May 2027. The drug showed strong trial results, offering a potential new treatment to help offset lost sales from older drugs.

  This is a new regulatory milestone that advances a promising pipeline drug.

• ▲

  Bristol expands AI drug discovery with NVIDIA and new San Diego hub Bristol is building the most powerful AI supercomputer in life sciences with NVIDIA and opened a 427,000-square-foot San Diego research hub. These investments aim to speed up drug discovery and improve pipeline efficiency, supporting long-term growth.

  These new technology investments could enhance BMY's ability to develop new drugs faster.

Based on 9 stories →

• ▲

  Three pipeline wins in two weeks Bristol reported positive late-stage results for three experimental drugs: SUCCESSOR-2 in multiple myeloma, izalontamab brengitecan in breast and esophageal cancer, and a CAR-T therapy with a 96% response rate. New treatments help replace sales lost as older drugs face cheaper copies.

  This is the main new force lifting BMY: fresh pipeline data that can offset patent losses.

• ▼

  Congress probes China trials A House committee opened an investigation into Bristol over clinical trials at Chinese military hospitals and in Xinjiang. This adds legal and reputational risk, and could lead to restrictions or penalties, which weighs on the stock.

  It is a new regulatory threat that could hurt BMY's reputation and operations.

• ▼

  Medicare price negotiation risk Proposed changes would make Medicare drug price negotiation permanent from 2029 and tighten rules on fixed-combination drugs. This could pressure future U.S. prices for some Bristol medicines, though legal challenges and a broad product mix may soften the blow.

  It flags a new pricing risk that could lower BMY's future revenue.

• ▼

  Roche rival beats Krazati Roche's divarasib outperformed Bristol's Krazati in a Phase III lung cancer trial, meeting survival goals. This competitive threat could erode Krazati's market share and future sales, a negative for BMY.

  It shows a new competitive loss that could reduce BMY's oncology revenue.

Based on 7 stories →